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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S463between subjects receivingABT-981orplacebo. A trend towardsdecreased
absolute neutrophil count (ANC) was observed in subjects receiving ABT-
981. TheANCaveragedemonstratedadose-dependentdecrease; thus,ANC
has potential utility as a PD biomarker. There were 2 transient grade 2
neutropenia events observed in the MAD study; both resolved sponta-
neously. Several inﬂammation (Fig A) and joint destruction/remodeling
(Fig B) biomarkers decreased after ABT-981 treatment; some of these
markers exhibited dose-dependent changes (eg, hsCRP, C3M, CRPM).
The phase 1 results supported initiation of a phase 2a proof-of-concept
study. This is a randomized, DB, parallel-group, placebo-controlled trial
to evaluate the safety, tolerability, efﬁcacy and PK/PD effect of ABT-981
in patients with symptomatic, radiographic, and inﬂammatory knee OA.
Approximately 320 patients will be randomized to 4 treatment groups
receiving ABT-981 or placebo E2W for 50 weeks (treatment period).
Patients will discontinue all analgesic medications during the washout
period through week 26. Afterwards, oral standard-of-care medications
will be permitted. The primary objective of the trial is to assess the
effect of ABT-981 on OA knee pain using the Western Ontario and
McMaster Universities OA Index from baseline to week 16, and syno-
vitis/effusion volume of the index knee using magnetic resonance
imaging (MRI) from baseline to week 26. The secondary objectives
include evaluating the safety and tolerability of ABT-981 and the effect
of ABT-981 on physical function, index knee resting and intermittent
pain, patient global assessment, and MRI structure parameters over 52
weeks. The change in joint space narrowing will also be assessed on
radiographs at week 52.
Conclusions: Results of the phase 1 trials demonstrated that ABT-981
was well tolerated in healthy subjects and knee OA patients, and sup-
port further investigation of ABT-981 in an OA population in the phase 2
trial.
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COMPARING THE DISEASE MODIFYING EFFECTS OF ALENDRONATE
TO RISEDRONATE IN THE RAT ANTERIOR CRUCIATE LIGAMENT
TRANSECTION MODEL OF OSTEOARTHRITIS
T. Hayami y,z, G. Wesolowski y, Z. Ya y, M. Pickarski y, L.T. Duong y. yBone
Biology. Merck Res Labs., West Point, PA. USA; z Saiseikai Niigata Daini
Hosp., Niigata, Japan
Purpose: Osteoarthritis (OA) is considered to be a disease of the whole
joint and subchondral bone remodeling has been proposed to con-
tribute to the initiation and progression of OA. We previously demon-
strated the bisphosphonate (BIS) alendronate (ALN) partially prevented
cartilage degradation and reduced periarticular bone remodeling in the
rat anterior cruciate ligament transection (ACLT) model of OA. Consid-
ering the osteoporosis doses of risedronate (RIS) and ALN are 35mg and
70 mg once-weekly, respectively, the clinical evaluation of RIS at 5 mg/
d, 15 mg/d, 35 mg/wk and 50 mg/wk for 2 years failed to demonstrate
disease modifying efﬁcacy in human OA. Hence, the purpose of the
current study is to directly compare efﬁcacy of ALN versus RIS in the rat
ACLT model.
Method: Skeletally mature male Sprague-Dawley rats (20-wks old)
were subjected to anterior cruciate ligament transection (ACLT, n ¼
42) or sham (ShamþV, n ¼ 7) surgery in the right knee. ACLT rats
were randomized into 5 treatment groups (n ¼ 7/group): vehicle
(ACLTþV), low dose ALN (0.06 mg/kg/wk, ACLTþL-ALN), high dose
ALN (0.12 mg/kg/wk, ACLTþH-ALN), low dose RIS (0.06 mg/kg/wk,
ACLTþL-RIS), or high dose RIS (0.12 mg/kg/wk, ACLTþH-RIS). The BIS
were administered at one week prior to the ACLT surgery via SQ,
twice-weekly for 10-weeks. Disarticulated femora were scored for
incidence of osteophyte formation. Proximal tibiae were trimmed
into anterior and posterior halves. Parafﬁn sections of the anterior
tibia were subjected to histological Mankin scoring. Plastic sections
of the posterior halves were stained with Masson’s trichrome and
subjected to histomorphometric assessments for osteophyte area.
Levels of urinary C-terminal telopeptide type II collagen (CTX-II) and
type I collagen (CTX-I) were determined to evaluate cartilage and
bone turnover.
Results: Historically, ALN at 0.03 mg/kg/wk is an effective dose to
fully prevent estrogen-deﬁcient bone loss in ovariectomized rats.
Hence, the two doses of ALN used in this study were w2- and 4-fold
of the equivalent osteoporosis dose in this species. Both doses of
ALN and RIS signiﬁcantly reduced the histological Mankin score of
cartilage damage by 20-35% as compared to ACLTþV. The BIS also
signiﬁcantly reduced osteophyte score and area compared to thevehicle treated ACLT-rats. Comparison of equivalent BIS doses dem-
onstrated ALN treatment was consistently more effective than RIS in
cartilage protection and reduction of osteophyte formation. Both BIS
displayed dose-related reductions of the cartilage degradation (CTX-
II) and bone resorption (CTX-I) markers. However, ALN at both doses
signiﬁcantly reduced these markers to a higher extent than the
respective RIS doses.
Conclusions: The results from this study suggest that a BIS at a dose
exceeding its osteoporosis dose is required to achieve inhibition of
cartilage matrix degradation and osteophyte formation in preclinical
models of OA. At the same administered dosages, ALN treatment was
more effective than RIS on cartilage protection and reduction of
osteophyte formation.
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A SINGLE INTRA-ARTICULAR DOSE OF FX006, AN EXTENDED-
RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE, HAS A
SIMILAR EFFECT ON CARTILAGE IN HEALTHY DOGS AS THE
COMMONLY USED KENALOG-40 SUSPENSION
A. Kumar y, A. Walz z, D. Garlick x, C. Spainhour z, N. Bodick y. y Flexion
Therapeutics, Burlington, MA, USA; zCalvert Lab., Olyphant, PA, USA;
xHisto-Scientiﬁc Res. Lab., Mt. Jackson, VA, USA
Purpose: FX006 is an extended-release poly(lactic-co-glycolic acid)
(PLGA) microsphere formulation of triamcinolone acetonide (TCA).
Following a single intra-articular (IA) injection, FX006 delivers TCA to
the knee joint for about 3 months as PLGA slowly biodegrades by
hydrolysis. It has been demonstrated that this prolonged delivery of TCA
from FX006 results in enhanced analgesic effect in patients with
osteoarthritis (OA). As part of the assessment of safety of FX006, single
IA doses of an approved injectable suspension of TCA (Kenalog-40;
TCA IR) or FX006 were injected into the knees of healthy dogs and the
effect on cartilage was evaluated over a period of time.
Methods: Anesthetized, healthy, male and female Beagle dogs received
1mL IA injections under aseptic conditions. Treatment groups included:
FX006, which contains 25% (w/w) TCA, at TCA doses of 18.75 mg
(maximum feasible high-dose; human equivalent dose about 60 mg),
6.2 mg or 2.1 mg; TCA IR to match high-dose FX006 (18.75 mg); blank
PLGA microspheres to match the total microsphere content of high-
dose FX006 (75 mg) and vehicle/diluent (1 mL). FX006 is reconstituted
with diluent to form a sterile suspension prior to IA injection. Groups of
animals were sacriﬁced at the following time points post-dosing: 3
days, 4 weeks, 6 weeks, 3, 4, 6 and 9 months, to assess acute and late
effects and the recovery of the same. At each time point, knee joints
were collected, processed, decalciﬁed, embedded in parafﬁn, and sec-
tioned to include the patella, distal femoral articular cartilage (condyle),
and proximal tibial articular cartilage (tibial plateau). One section was
stained with hematoxylin and eosin and a second section with Safranin
O for glycosaminoglycans (GAGs) in the extracellular matrix. These
were evaluated to assess articular cartilage morphology by employing
the Mankin scale. In this semi-quantitative scoring system, cartilage
structure, cellularity, Safranin O staining and tidemark integrity are
scored on scales of 0-6, 0-3, 0-4 and 0-1 respectively to yield a total
Mankin score from 0-14, with 0 indicating normal.
Results: Total Joint Average Mankin Scores from the proximal tibia,
distal femur and patellar bone sections are summarized in Table 1
below for all time points evaluated. Overall the Mankin scores were
low and the only change resulting in an increase from the normal score
of 0 was due to a loss in Safranin O staining, indicating loss of GAGs in
the extracellular matrix of articular cartilage, in all TCA-treated joints.
The scores were comparable in TCA IR and FX006-treated knees with
no dose-dependence in the FX006 groups. The loss of Safranin O
appeared 3 days after IA injection of either TCA IR or FX006 and peaked
at 4-6 weeks. This effect was still apparent 3 months post-injection and
starting to recover but was still notable at 4 months. By 6 months,
Safranin O staining was clearly recovering indicating a restoration of, or
increase in secretion of matrix by chondrocytes. This recovery also was
comparable between the TCA IR and FX006 treatment groups at all
dose levels. By 9 months after dosing with either TCA IR or FX006,
normal Safranin O staining was restored. No adverse effects on carti-
lage cellularity, structure (such as appearance of surface irregularities,
pannus, clefts), tidemark integrity or on sub-chondral bone were evi-
dent in joints treated with either TCA IR or FX006 at any time point. No
effect on cartilage as judged by any component of the Mankin score
was noted following injection of blank PLGA microspheres or diluent at
